Financhill
Back

Nuvalent Quote, Financials, Valuation and Earnings

Nuvalent Price Quote

$84.24
+0.09 (+-0.47%)
(Updated: December 21, 2024 at 5:39 AM ET)

Nuvalent Key Stats

Sell
13
Nuvalent (NUVL) is a Sell

Day range:
$82.81 - $87.32
52-week range:
$61.80 - $113.51
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
5.33%

Volume:
1M
Avg. volume:
421.2K
1-year change:
16.78%
Market cap:
$6B
Revenue:
$0
EPS:
$-3.47

How Much Does Nuvalent Make?

Data Unavailable

Is Nuvalent Growing As A Company?

Data Unavailable

Nuvalent Stock Price Performance

  • Did Nuvalent Stock Go Up Last Month?
    Nuvalent share price went down by -7.7% last month
  • Did NUVL's Share Price Rise Over The Last Year?
    NUVL share price rose by 16.78% over the past 1 year

What Is Nuvalent 52-Week High & Low?

  • What Is Nuvalent’s 52-Week High Share Price?
    Nuvalent has traded as high as $113.51 over the past 52 weeks
  • What Is Nuvalent’s 52-Week Low Share Price?
    Nuvalent has traded as low as $61.80 over the past 52 weeks

Nuvalent Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Nuvalent?

Data Unavailable

Is Nuvalent Cash Flow Positive?

Data Unavailable

Nuvalent Return On Invested Capital

Data Unavailable

Nuvalent Earnings Date & Stock Price

  • What Is Nuvalent's Stock Price Today?
    A single share of NUVL can be purchased today for 84.15
  • What Is Nuvalent’s Stock Symbol?
    Nuvalent trades on the nasdaq under the ticker symbol: NUVL
  • When Is Nuvalent’s Next Earnings Date?
    The next quarterly earnings date for Nuvalent is scheduled on February 27, 2025
  • When Is NUVL's next ex-dividend date?
    Nuvalent's next ex-dividend date is December 21, 2024
  • How To Buy Nuvalent Stock?
    You can buy Nuvalent shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Nuvalent Competitors

  • Who Are Nuvalent's Competitors?
    Below is a list of companies who compete with Nuvalent or are related in some way:
    • iBio Inc (IBIO)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Theriva Biologics Inc (TOVX)
    • Viking Therapeutics Inc (VKTX)

Nuvalent Dividend Yield

Data Unavailable

Nuvalent Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -44.2%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 115.50
Upside from Last Price: 37.25%

Major Shareholders

Data Unavailable